Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome

International Journal of Pharmaceutics

Volumn 346, Issue 1-2, 2008, Pages 143-150

  Suzuki, Ryo ^a   Takizawa, Tomoko ^a   Kuwata, Yasuhiro ^a   Mutoh, Mahito ^a   Ishiguro, Nobuyuki ^a   Utoguchi, Naoki ^a   Shinohara, Atsuko ^b   Eriguchi, Masazumi ^c   Yanagie, Hironobu ^c   Maruyama, Kazuo ^a  

^a TEIKYO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cancer therapy; Liposomes; Oxaliplatin; Polyethyleneglycol (PEG); Targeting; Transferrin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LIPOSOME; MACROGOL; OXALIPLATIN; TRANSFERRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; ENCAPSULATION; ERYTHROCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; ERYTHROCYTES; KIDNEY; LIPOSOMES; LIVER; LUNG; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; ORGANOPLATINUM COMPOUNDS; POLYETHYLENE GLYCOLS; SPLEEN; TISSUE DISTRIBUTION; TRANSFERRIN;

EID: 36049008819     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2007.06.010     Document Type: Article

References (29)

1. Aisen P. The transferrin receptor and the release of iron from transferrin. Adv. Exp. Med. Biol. 356 (1994) 31-40
2. Bomford A.B., and Munro H.N. Transferrin and its receptor: their roles in cell function. Hepatology 5 (1985) 870-875
3. Durant J.R. Cisplatin: a clinical overview. In: Prestayko A.W., Crooke S.T., and Cater S.K. (Eds). Cisplatin: Current Status and New Developments (1980) 317-321
4. Dvorak H.F., Nagy J.A., Dvorak J.T., and Dvorak A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133 (1988) 95-109
5. Extra J.M., Espie M., Calvo F., Ferme C., Mignot L., and Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol. 25 (1990) 299-303
6. Goldberg R.M., Sargent D.J., Morton R.F., Fuchs C.S., Ramanathan R.K., Williamson S.K., Findlay B.P., Pitot H.C., and Alberts S.R. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22 (2004) 23-30
7. Hatakeyama H., Akita H., Maruyama K., Suhara T., and Harashima H. Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivo. Int. J. Pharm. 281 (2004) 25-33
8. Huebers H.A., and Finch C.A. The physiology of transferrin and transferrin receptors. Physiol. Rev. 67 (1987) 520-582
9. Iinuma H., Maruyama K., Okinaga K., Sasaki K., Sekine T., Ishida O., Ogiwara N., Johkura K., and Yonemura Y. Intracellular targeting therapy of cisplatin-encapsulated transferring-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int. J. Cancer 99 (2002) 130-137
10. Ishida O., Maruyama K., Sasaki K., and Iwatsuru M. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int. J. Pharm. 190 (1999) 49-56
11. Ishida O., Maruyama K., Tanahashi H., Iwatsuru M., Sasaki K., Eriguchi M., and Yanagie H. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 18 (2001) 1042-1048
12. Jain R.K., and Gerlowski L.E. Extravascular transport in normal and tumor tissues. Crit. Rev. Oncol. Hematol. 5 (1986) 115-170
13. Jefferies W.A., Brandon M.R., Hunt S.V., Williams A.F., Gatter K.C., and Mason D.Y. Transferrin receptor on endothelium of brain capillaries. Nature 312 (1984) 162-163
14. Kakudo T., Chaki S., Futaki S., Nakase I., Akaji K., Kawakami T., Maruyama K., Kamiya H., and Harashima H. Transferrin-modified liposomes equipped with a pH-sensitive fusogenic peptide: an artificial viral-like delivery system. Biochemistry 43 (2004) 5618-5628
15. Kidani Y., Noji M., and Tashiro T. Antitumor activity of platinum(II) complexes of 1,2-diamino-cyclohexane isomers. Gann 71 (1980) 637-643
16. Kono K., Igawa T., and Takagishi T. Cytoplasmic delivery of calcein mediated by liposomes modified with a pH-sensitive poly(ethylene glycol) derivative. Biochim. Biophys. Acta 1325 (1997) 143-154
17. Machover D., Diaz-Rubio E., de Gramont A., Schilf A., Gastiaburu J.J., Brienza S., Itzhaki M., Metzger G., N'Daw D., Vignoud J., Abad A., Francois E., Gamelin E., Marty M., Sastre J., Seitz J.F., and Ychou M. Two consecutive phase II studies of oxaliplatin (l-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol. 7 (1996) 95-98
18. Maruyama K., Ishida O., Kasaoka S., Takizawa T., Utoguchi N., Shinohara A., Chiba M., Kobayashi H., Eriguchi M., and Yanagie H. Intracellular targeting of sodium mercaptoundecahydrododecaborate (BSH) to solid tumors by transferrin-PEG liposomes, for boron neutron-capture therapy (BNCT). J. Control. Rel. 98 (2004) 195-207
19. Maruyama K., Takahashi N., Tagawa T., Nagaike K., and Iwatsuru M. Immunoliposomes bearing polyethyleneglycol-coupled Fab' fragment show prolonged circulation time and high extravasation into targeted solid tumors in vivo. FEBS Lett. 413 (1997) 177-180
20. Maruyama K., Takizawa T., Yuda T., Kennel S.J., Huang L., and Iwatsuru M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal antibodies. Biochim. Biophys. Acta 1234 (1995) 74-80
21. Maruyama K., Unezaki S., Takahashi N., and Iwatsuru M. Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia. Biochim. Biophys. Acta 1149 (1993) 209-216
22. Mathe G., Kidani Y., Segiguchi M., Eriguchi M., Fredj G., Peytavin G., Misset J.L., Brienza S., de Vassals F., Chenu E., et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother. 43 (1989) 237-250
23. Matsumura Y., and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46 (1986) 6387-6392
24. Miyajima Y., Nakamura H., Kuwata Y., Lee J.D., Masunaga S., Ono K., and Maruyama K. Transferrin-loaded nido-carborane liposomes: tumor-targeting boron delivery system for neutron capture therapy. Bioconjug. Chem. 17 (2006) 1314-1320
25. Pendyala L., and Creaven P.J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 53 (1993) 5970-5976
26. Pendyala L., Kidani Y., Perez R., Wilkes J., Bernacki R.J., and Creaven P.J. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett. 97 (1995) 177-184
27. Rothenberg M.L., Oza A.M., Bigelow R.H., Berlin J.D., Marshall J.L., Ramanathan R.K., Hart L.L., Gupta S., Garay C.A., Burger B.G., Le Bail N., and Haller D.G. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J. Clin. Oncol. 21 (2003) 2059-2069
28. Tashiro T., Kawada Y., Sakurai Y., and Kidani Y. Antitumor activity of a new platinum complex, oxalato(trans-l-1,2-diaminocyclohexane)platinum(II): new experimental data. Biomed. Pharmacother. 43 (1989) 251-260
29. Wagner E., Curiel D., and Cotton M. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv. Drug Deliv. Rev. 14 (1994) 113-135